Hugh McMillan
Professor, Department of Pediatrics, University of Ottawa
Pediatric Neurologist and Neuromuscular specialist at the Children’s Hospital of Eastern Ontario
Email HughDr. McMillan is a Pediatric Neurologist with specialization in Clinical Neurophysiology and Neuromuscular medicine at the Children’s Hospital of Eastern Ontario. He is a Professor in the Department of Pediatrics, Faculty of Medicine at the University of Ottawa. He holds a Clinical Research Chair (Level 2) at the University of Ottawa and is a Clinical Investigator at the CHEO Research Institute
He has been an author of over 125 publications in peer-review journals and was a co-editor of a Pediatric Electromyography textbook. He is also a leader in clinical and translational research in pediatric neurology & neuromuscular medicine.
Dr. McMillan completed a Neuromuscular and Neurophysiology Fellowship at Boston Children’s Hospital, Harvard University and the Lahey Clinic, Tufts University; a Pediatric Neurology Residency at the Children’s Hospital of Eastern Ontario, University of Ottawa and a Pediatric Residency at McMaster Children’s Hospital, McMaster University.
Read more about Hugh
Recent publications
Sbrocchi, AM, Ahmet, A, Kinnett, K, Lautatzis, ME, McMillan, HJ, Apkon, S et al.. A structured approach to address variability in the global management of adrenal insufficiency in Duchenne muscular dystrophy: the 2025 PJ Nicholoff steroid protocol. Front Neurol. 2026.17 1926817 PMID:42787106
Weber, DR, Ahmet, A, Kinnett, K, Lautatzis, ME, McMillan, HJ, Apkon, S et al.. Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions. J Neuromuscul Dis. 2026. 22143602261485046 PMID:42770351
Orbach, R, Gil Garzon, MR, Büning, H, Bönnemann, C, Muntoni, F, 289th ENMC Workshop participants et al.. 289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands. Neuromuscul Disord. 2026. 107371 PMID:42668237
Halloun, R, Jackowski, S, Scharke, M, Dang, UJ, Alshammri, F, Ma, J et al.. Total body and appendicular lean mass by dual-energy X-ray absorptiometry are highly associated with muscle function and bone mineral density in Becker muscular dystrophy. J Neuromuscul Dis. 2026. 22143602261476364 PMID:42663311
Sutton, ER, Beauvais, A, Yaworski, R, McMillan, HJ, Kothary, R. Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy. Ann Neurol. 2026.100 (3)584-599 PMID:42458739
Degan, C, Tobin, RA, de Vries, SI, Jiménez-Requena, A, Peco, A, Guglieri, M et al.. Evaluation of a serum protein signature as monitoring biomarker for Duchenne muscular dystrophy in a long-term clinical trial with corticosteroids. Skelet Muscle. 2026. PMID:42443978
Nasomyont, N, Appel, A, Apkon, S, Hoskin, J, Surampudi, PN, Truba, N et al.. Navigating sexual health, fertility, and adult wellness in individuals with Duchenne muscular dystrophy: Current standards of care and future directions. J Neuromuscul Dis. 2026. 22143602261454423 PMID:42439098
Mah, JK, Lochmüller, H, Ward, L, Selby, K, Gonorazky, H, Sbrocchi, AM et al.. Expanding Vamorolone Treatment Access for Canadians with Duchenne Muscular Dystrophy. Can J Neurol Sci. 2026. 1-4 PMID:42438401
Alazem, H, Friesen, AH, Dennison, T, Nizam, A, Larin, ML, Longmuir, PE et al.. Mobile robotic walker enables precision moderately intense exercise and environmental exploration in a child with cerebral palsy GMFCS IV: assessment of use, user experience and quantitative impact in a home and hospital based setting. Disabil Rehabil Assist Technol. 2026.21 (6)3317-3327 PMID:42423986
Poulin, KL, René, CA, Smith, IC, Vacratsis, PO, Burger, D, McMillan, HJ et al.. Extracellular vesicles as biomarkers of disease progression and therapeutic response in patients with spinal muscular atrophy. Mol Ther Adv. 2026.34 (2)201757 PMID:42232219
See more on PubMed